Updated Jul 28, 7:27 PM · 60 sources analyzed
Key Takeaways
Genfit's VS-01 Phase 2 trial in acute-on-chronic liver failure was terminated with no data disclosed, a pipeline setback for the rebuilding company.
Amgen completed three Phase 3 rocatinlimab studies in atopic dermatitis, signaling a maturing regulatory package ahead of a likely BLA filing.
MapLight Therapeutics filed a material 8-K (Items 7.01/8.01) warranting close review; content not yet publicly detailed.
🏆 Winner
Amgen — completion of multiple Phase 3 rocatinlimab studies across populations advances its atopic dermatitis regulatory dossier toward a potential submission.
📉 Loser
Genfit — termination of the VS-01 Phase 2 ACLF trial without disclosed data removes a key pipeline asset from the company's near-term story.
🔭 Watch Next
Akero Therapeutics' SYNCHRONY Phase 3 histology readout in F4 NASH cirrhosis — expected in 2026–2027 — will be the most consequential near-term event visible in today's sources for investors tracking the post-resmetirom NASH landscape.
MapLight Therapeutics files material 8-K disclosing new information
MapLight Therapeutics (watchlist: MPLT) filed an 8-K on July 27, 2026, disclosing items 7.01, 8.01, and 9.01 — a combination that typically signals a material corporate or scientific announcement, not routine governance. Item 8.01 in particular is a catch-all for material events, suggesting this could involve a pipeline update, partnership, or other significant development. Without the full exhibit text, the precise nature remains unconfirmed, but the 8.01 filing category warrants close attention from investors tracking this early-stage neuropsychiatry-focused biotech.
SEC EDGAR ↗Genfit
VS-01 in Acute-on-Chronic Liver Failure (ACLF) with Ascites
The UNVEIL-IT Phase 2 trial of VS-01 (an intraperitoneal liposomal formulation) in patients with acute-on-chronic liver failure and ascites was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in conjunction with this status update; full data are expected at a future publication or medical meeting.
Why it matters
Genfit has been rebuilding its pipeline after the elafibranor NASH setback, and VS-01 represented a differentiated delivery strategy in a severe liver disease niche with unmet need. A terminated Phase 2 before disclosed data is a credibility setback for the program; investors will want to understand whether this was a futility call, safety signal, or operational issue before reassessing the pipeline.
What to watch
Watch for a Genfit press release or investor communication explaining the termination rationale and whether any data will be presented at a liver disease conference such as EASL or The Liver Meeting in late 2026.
Genfit
Genfit terminates Phase 2 UNVEIL-IT trial of VS-01 in acute-on-chronic liver failure with ascites.
The termination eliminates Genfit's most advanced liver failure asset from near-term pipeline contributions and narrows the company's commercial optionality in a high-unmet-need indication.
Why it matters
Genfit has been in rebuilding mode since its 2020 NASH setback with elafibranor, and VS-01's termination — without a transparent efficacy or safety explanation — raises questions about the company's pipeline resilience and ability to attract partnering interest in the liver disease space. Investors will want a clear explanation of whether this was a safety-driven decision or a strategic resource reallocation.
What to watch
Watch for a Genfit corporate update or press release within the next 30 days clarifying the termination rationale and any revised pipeline prioritization.
Triple Artemisinin-Based Combination Therapy Evaluated for Malaria Drug Resistance Delay
A Phase 2/3 randomized trial (NCT05764746) run by Muhimbili University in Tanzania evaluated triple artemisinin-based combination therapy (TACT) for uncomplicated Plasmodium falciparum malaria, with the goal of delaying resistance emergence; the study has been marked Completed on ClinicalTrials.gov.
Why it matters
Artemisinin resistance spreading from Southeast Asia into sub-Saharan Africa is one of the most serious threats in global health; a positive TACT dataset would validate a combination strategy that does not require entirely novel mechanisms and could accelerate WHO guideline revision, creating a near-term deployment pathway for existing drugs in new combinations.
What to watch
Watch for peer-reviewed publication of TACT efficacy and parasite clearance data from this Tanzanian cohort, and for WHO Malaria Policy Advisory Group review of TACT evidence anticipated in 2026–2027.
Brii Biosciences Phase 2 HBV Combination Therapy Study Completed
Brii Biosciences' Phase 2 study (NCT04749368) evaluating BRII-835 (VIR-2218, an RNAi agent targeting HBV surface antigen) plus BRII-179 (VBI-2601, a recombinant HBV antigen therapeutic vaccine) in chronic hepatitis B was marked Completed on ClinicalTrials.gov.
Why it matters
The completion of this combination study is scientifically relevant because pairing RNAi-mediated surface antigen suppression with immune priming via a therapeutic vaccine is one of the most mechanistically coherent paths toward functional HBV cure; published data from this cohort will help the field calibrate whether antigen reduction plus immune restoration is sufficient or whether additional immune checkpoint modulation is needed.
What to watch
Watch for peer-reviewed publication of HBsAg loss rates and T-cell response data from this cohort, and for any Phase 3 advancement announcement from Brii Biosciences or its partner Vir Biotechnology.
The UNVEIL-IT Phase 2 trial of VS-01 (an intraperitoneal liposomal formulation) in patients with acute-on-chronic liver failure and ascites was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released in conjunction with this status update; full data are expected at a future publication or medical meeting.
Why it matters
ACLF is a high-mortality condition with no approved pharmacologic therapies, and termination of a Phase 2 study — even without disclosed reasons — narrows the near-term field of novel intraperitoneal approaches.
Analysis
Genfit has been rebuilding its pipeline after the elafibranor NASH setback, and VS-01 represented a differentiated delivery strategy in a severe liver disease niche with unmet need. A terminated Phase 2 before disclosed data is a credibility setback for the program; investors will want to understand whether this was a futility call, safety signal, or operational issue before reassessing the pipeline.
What to watch
Watch for a Genfit press release or investor communication explaining the termination rationale and whether any data will be presented at a liver disease conference such as EASL or The Liver Meeting in late 2026.
Three separate Amgen rocatinlimab Phase 3 trials — a safety/tolerability study in adolescents (NCT05633355), a vaccine antibody response study (ROCKET-VOYAGER, NCT05899816), and a monotherapy efficacy study (ROCKET-IGNITE, NCT05398445) — were all marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data were disclosed in conjunction with these registry status changes.
Why it matters
Completion of multiple Phase 3 rocatinlimab studies across age groups and safety subquestions signals that Amgen's regulatory package for an OX40 ligand inhibitor in atopic dermatitis is maturing, though actual results will determine competitive positioning against dupilumab and tralokinumab.
Analysis
Rocatinlimab occupies a differentiated mechanistic slot in atopic dermatitis, and completing Phase 3 studies — including a pediatric arm and an immunogenicity (vaccine response) safety substudy that regulators often require — suggests Amgen may be assembling a submission-ready dossier. The investment question is whether efficacy and durability data, when released, justify formulary positioning against entrenched IL-4/IL-13 blockers.
What to watch
Watch for full data presentations from ROCKET-IGNITE and the adolescent study at AAD or EADV in late 2026 or early 2027, and any BLA filing announcement from Amgen.
The Phase 3 CodeBreak 300 study (NCT05198934) comparing sotorasib 240 mg plus panitumumab versus investigator's choice in previously treated KRAS p.G12C-mutated CRC was marked Completed on ClinicalTrials.gov. No updated efficacy or survival data were disclosed alongside this registry status change; previously reported topline PFS data had already been presented publicly.
Why it matters
Study completion closes the data-collection phase of the only randomized Phase 3 dataset for a KRAS G12C inhibitor combination in CRC, and any mature overall survival analysis from this cohort will be closely watched by oncologists and competing KRAS programs.
Analysis
Sotorasib's CRC path has been complicated by modest single-agent activity and competitive pressure from next-generation KRAS inhibitors; the completion of CodeBreak 300 and any forthcoming OS update will determine whether the combination can defend its label foothold against adagrasib-based regimens and emerging KRAS G12C-selective degraders.
What to watch
Watch for a mature overall survival data cut from CodeBreak 300 to be presented at ASCO or ESMO in the next 6–12 months.
Boehringer Ingelheim's Phase 2 dose-ranging study of BI 1291583 in adults with bronchiectasis (NCT05238675) was marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data were disclosed alongside this registry status update; full data are expected at a future medical meeting or publication.
Why it matters
Bronchiectasis is a growing area of drug development with limited approved options, and a completed Phase 2 dose-finding study from a major respiratory player sets the stage for a potential Phase 3 decision.
Analysis
Boehringer Ingelheim has been building a respiratory portfolio, and BI 1291583 — a CXCR2 antagonist targeting neutrophilic inflammation — addresses a mechanism with biological plausibility in bronchiectasis exacerbations. The Phase 2 completion positions the company for a Phase 3 decision, which will sharpen competitive dynamics against AstraZeneca's brensocatib (already in Phase 3 with positive data) and tezepelumab-based strategies.
What to watch
Watch for Phase 2 data presentation at a respiratory congress such as ERS 2026 (September) and any Phase 3 advancement announcement from Boehringer Ingelheim.
Akero Therapeutics' Symmetry Phase 2 study of efruxifermin in biopsy-proven F4 compensated NASH cirrhosis (NCT05039450) was marked Completed on ClinicalTrials.gov. No outcome data were disclosed alongside this registry status change; previously, Akero has reported biopsy-based histologic improvement data from this cohort publicly.
Why it matters
Formal completion of the Symmetry study closes the Phase 2 data-collection window for efruxifermin in the hardest-to-treat NASH population — compensated cirrhotics — where Madrigal's resmetirom does not yet have a label.
Analysis
Efruxifermin is one of the few FGF21 analogs with biopsy-proven histologic data in cirrhotic NASH patients, a population that resmetirom's approved label excludes, giving Akero a credible differentiation angle if Phase 3 data hold. The Symmetry completion keeps the Phase 3 SYNCHRONY cirrhosis cohort as the critical value driver to watch.
What to watch
Watch for interim or topline data from the SYNCHRONY Histology Phase 3 trial in F4 NASH, expected in 2026–2027, which will be the pivotal dataset for Akero's regulatory path in cirrhosis.
Triple Artemisinin-Based Combination Therapy Evaluated for Malaria Drug Resistance Delay
A Phase 2/3 randomized trial (NCT05764746) run by Muhimbili University in Tanzania evaluated triple artemisinin-based combination therapy (TACT) for uncomplicated Plasmodium falciparum malaria, with the goal of delaying resistance emergence; the study has been marked Completed on ClinicalTrials.gov.
Why it matters
If TACT demonstrates non-inferior efficacy with a resistance-delaying effect compared to standard ACT doublets, it could reshape first-line malaria treatment guidelines and inform the pipeline strategy for antimalarial developers facing increasing artemisinin partial resistance in Africa.
Analysis
Artemisinin resistance spreading from Southeast Asia into sub-Saharan Africa is one of the most serious threats in global health; a positive TACT dataset would validate a combination strategy that does not require entirely novel mechanisms and could accelerate WHO guideline revision, creating a near-term deployment pathway for existing drugs in new combinations.
What to watch
Watch for peer-reviewed publication of TACT efficacy and parasite clearance data from this Tanzanian cohort, and for WHO Malaria Policy Advisory Group review of TACT evidence anticipated in 2026–2027.
Mirdametinib Plus Sirolimus Combination Suspended in RAS-Mutated Relapsed/Refractory Myeloma
An NCI-sponsored Phase 1/2 study (NCT06876142) combining mirdametinib (a MEK inhibitor) and sirolimus (an mTOR inhibitor) for RAS-mutated relapsed/refractory multiple myeloma was placed on Suspended status on ClinicalTrials.gov.
Why it matters
A suspension — distinct from termination — often signals a clinical hold or safety review rather than futility, and the outcome will have implications for dual RAS-pathway inhibition strategies in hematologic malignancies, an area gaining traction as RAS mutation profiling becomes standard in myeloma.
Analysis
RAS mutations occur in roughly 20–25% of myeloma patients at relapse and represent an actionable but underexplored target; a safety-driven suspension in this NCI study could slow the field's enthusiasm for MEK/mTOR co-inhibition in a fragile patient population, though the academic sponsorship limits direct commercial read-through to biotech pipelines pursuing similar combinations.
What to watch
Watch for NCI or ClinicalTrials.gov updates on the suspension rationale and whether the study resumes, which would indicate the safety concern was addressable versus a more fundamental tolerability barrier.
Brii Biosciences Phase 2 HBV Combination Therapy Study Completed
Brii Biosciences' Phase 2 study (NCT04749368) evaluating BRII-835 (VIR-2218, an RNAi agent targeting HBV surface antigen) plus BRII-179 (VBI-2601, a recombinant HBV antigen therapeutic vaccine) in chronic hepatitis B was marked Completed on ClinicalTrials.gov.
Why it matters
The RNAi-plus-therapeutic-vaccine combination strategy aims at functional cure — defined as sustained HBsAg (surface antigen) loss off therapy — which remains the holy grail in HBV drug development and directly competes with approaches from Vir Biotechnology, Assembly Biosciences, and Gilead.
Analysis
The completion of this combination study is scientifically relevant because pairing RNAi-mediated surface antigen suppression with immune priming via a therapeutic vaccine is one of the most mechanistically coherent paths toward functional HBV cure; published data from this cohort will help the field calibrate whether antigen reduction plus immune restoration is sufficient or whether additional immune checkpoint modulation is needed.
What to watch
Watch for peer-reviewed publication of HBsAg loss rates and T-cell response data from this cohort, and for any Phase 3 advancement announcement from Brii Biosciences or its partner Vir Biotechnology.
Genfit
Genfit terminates Phase 2 UNVEIL-IT trial of VS-01 in acute-on-chronic liver failure with ascites.
Why it matters
The termination eliminates Genfit's most advanced liver failure asset from near-term pipeline contributions and narrows the company's commercial optionality in a high-unmet-need indication.
Analysis
Genfit has been in rebuilding mode since its 2020 NASH setback with elafibranor, and VS-01's termination — without a transparent efficacy or safety explanation — raises questions about the company's pipeline resilience and ability to attract partnering interest in the liver disease space. Investors will want a clear explanation of whether this was a safety-driven decision or a strategic resource reallocation.
What to watch
Watch for a Genfit corporate update or press release within the next 30 days clarifying the termination rationale and any revised pipeline prioritization.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
MapLight Therapeutics filed an 8-K on July 27, 2026 disclosing Items 7.01 (Regulation FD disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The combination of Items 7.01 and 8.01 suggests a material corporate or pipeline disclosure was made to investors, though the full content of the exhibit has not been summarized in available sources.
SEC EDGAR ↗